Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 379 of the 385 references it cites were found in a registry or an index; 10 of the 34 sources its claims cite were checked for support.

Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis

Open access
Brouwer, Matthijs C., Tunkel, Allan R., van de Beek, Diederik · 2010 · Clinical Microbiology Reviews

Abstract

The epidemiology of bacterial meningitis has changed as a result of the widespread use of conjugate vaccines and preventive antimicrobial treatment of pregnant women. Given the significant morbidity and mortality associated with bacterial meningitis, accurate information is necessary regarding the important etiological agents and populations at risk to ascertain public health measures and ensure appropriate management. In this review, we describe the changing epidemiology of bacterial meningitis in the United States and throughout the world by reviewing the global changes in etiological agents followed by specific microorganism data on the impact of the development and widespread use of conjugate vaccines. We provide recommendations for empirical antimicrobial and adjunctive treatments for clinical subgroups and review available laboratory methods in making the etiological diagnosis of bacterial meningitis. Finally, we summarize risk factors, clinical features, and microbiological diagnostics for the specific bacteria causing this disease.

Overview

CoChat Summary

TL;DR

This narrative review describes the changing global epidemiology of acute bacterial meningitis, emphasizing the impact of conjugate vaccines, and summarizes laboratory diagnosis and antimicrobial treatment by clinical subgroup and pathogen. It reports major declines in Hib and pneumococcal meningitis after vaccination, while noting serotype replacement and a persistent high burden in developing countries.

Key findings

  • Before Hib conjugate vaccine, *H. influenzae* caused 45–48% of US bacterial meningitis cases; afterward it accounted for 7%. Industrialized nations saw >90% decreases (some >95%), developing-country vaccine efficacy was 88–94%, and the mean age of US cases rose from 15 months in 1986 to 25 years in 1995.
  • *S. pneumoniae* became the most common agent in the US and Europe, accounting for 61% of US cases. Heptavalent pneumococcal conjugate vaccine efficacy was 97.4% against vaccine serotypes; pneumococcal meningitis declined 59% in children <2 years, and incidence fell from 0.8 to 0.55 per 100,000 (33% decline), though serotypes 19A, 22F, and 35B emerged.
  • In 2008 US meningococcal disease, serogroups B (32%), C (32%), and Y (24%) predominated, causing meningitis in 53% of cases. The UK serogroup C conjugate vaccine program reduced serogroup C invasive disease by 81% overall, with short-term effectiveness of 92% in toddlers and 97% in adolescents and a 66% reduction in carriage among students aged 15–17.
  • Historical CDC 1978–1981 data included 13,974 cases, with an overall attack rate of 3.0 per 100,000; children <1 year had 76.7 per 100,000, and *H. influenzae*, *N. meningitidis*, and *S. pneumoniae* caused >80% of cases.

Methods

  • Narrative review of global epidemiology, conjugate vaccine impact, laboratory diagnosis, and antimicrobial/adjunctive therapy by clinical subgroup and specific pathogen.
  • Synthesizes data from CDC and other surveillance systems, vaccine trials, and published studies; no systematic search, inclusion criteria, or meta-analysis is described.
  • Main analysis is qualitative synthesis and expert recommendations, not primary data collection.

Limitations

  • The paper states that historical incidence studies were retrospective, used small populations, and had significant underreporting; the 1978–1981 CDC study lacked active case detection.
  • The paper notes no US epidemiological data on the tetravalent meningococcal conjugate vaccine’s impact and that 23-valent pneumococcal polysaccharide vaccine efficacy against meningitis has never been proven, with wide confidence intervals.
  • Evident from the text: as a narrative review, it lacks systematic search and quality appraisal and relies on heterogeneous surveillance and vaccine studies.

Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1128/cmr.00070-09

Cites

379 of 379 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

8 Valid · 2 Not valid · 13 Not checked · 3 Own results and interpretations

  • It may state two separate claims as one. 16
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 385 references

Research works printed but not linked: 2

  1. Centers for Disease Control and Prevention. 2008. Progress in introduction of pneumococcal conjugate vaccine—worldwide, 2000-2008. MMWR Morb. Mortal. Wkly. Rep.57:1148-1151.
  2. Greenwood, B. M. 1987. The epidemiology of acute bacterial meningitis in tropical Africa, p. 93-113. In J. D. Williams and J. Burnie (ed.), Bacterial meningitis. Academic Press, London, United Kingdom.

Cited by

See all 930

Metadata

Authors
Brouwer, M. C., Tunkel, A. R., & van de Beek, D.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Monmouth Medical Center (US)
  • Department of Neurology, Center of Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Venue
Clinical Microbiology Reviews
Published
2010-07
Volume
23
Issue
3
Pages
467-492
ISSN
  • 0893-8512 (ISSN-L)
  • 1098-6618
OpenAlex
W2108054631
Cited by
930
References
385
Citations by year
2026: 55 · 2025: 51 · 2024: 70 · 2023: 57 · 2022: 78 · 2021: 73 · 2020: 68 · 2019: 65 · 2018: 57 · 2017: 77 · 2016: 83 · 2015: 56 · 2014: 40 · 2013: 45 · 2012: 37
FWCI
3.65
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Clinical Microbiology Reviews (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
Funders
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (916.76.023)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
Keywords
acute bacterial meningitis, epidemiology, conjugate vaccines, etiological agents, empirical antimicrobial treatment, adjunctive therapy, laboratory diagnosis, risk factors, clinical features, Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b, Haemophilus influenzae type a, Listeria monocytogenes, Salmonella meningitis, Escherichia coli meningitis, meningococcal serogroups
MeSH terms
Anti-Bacterial Agents, Bacteria, Bacterial Vaccines, Bacteriological Techniques, Cross Infection, Humans, Immunocompromised Host, Meningitis, Bacterial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis. https://app.cochat.ai/papers/10.1128/cmr.00070-09
The paper
Brouwer, M. C., Tunkel, A. R., & van de Beek, D. (2010). Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis. Clinical Microbiology Reviews. https://doi.org/10.1128/cmr.00070-09

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.